CIOMS I form to the ICH E2B format

ent is to link fields in CIOMS I reporting form with data elements in the international transfer format ICH E2B (R2

MS I there are corresponding data elements in ICH E2B. However, ICH E2B is a flexible electronic format with h as structured information and in free text) intended for data transfer between different databases. CIOMS I is a pure reporting form with limited amount of fields (less structured and mostly in free text).

This implies some challenges in the mapping of data between **CIOMS I** and ICH E2B and therefore the table with suggestions in this document should only work as an overview and a guideline.

For example, the free text field 'DESCRIBE REACTION(S)' in **CIOMS I** can be linked to several structured and free text data elements in ICH E2B. See page 4-5 in table below.

For more detailed descriptions, please click on the links for ICH E2B (R2 and R3) guidelines;

ICH E2B (R2) Individual Case Safety Report (ICSR) Specification and Related Files http://estri.ich.org/e2br22/index.htm

ICH E2B (R3) Individual Case Safety Report (ICSR) Specification and Related Files http://estri.ich.org/e2br3/index.htm

SUSPECT ADVERSE REACTION REPORT													
					T	Τ	П	П		T	П		
	I. REACTION	INFORM	ΛΑΤΙΟΙ	N	•		1-1-						_
1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET				- O IZ OIIEON MEE									
(first, last) Day Month Year Years Day Month Year				APPROPRIATE TO ADVERSE REACTION									
7 + 13 DESCRIBE REACT	TON(S) (including relevant test	s/lab data	1)					_	7		NT [DIED	
				☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION				ı					
					☐ INVOLVED PERSISTENCE OR SIGNIFICANT DISABILITY OR INCAPACITY								
					☐ LIFE THREATENING								
	II. SUSPECT DRUG	G(S) INF	ORMA	OITA	V								
14. SUSPECT DRUG(S) (incl	ude generic name)								AB	ATE	ACT AF NG D NO	TER RUG	?
15. DAILY DOSE(S)			16. ROUTE(S) OF ADMINISTRATION 21. DID REACTION REAPPEAR AFTER REINTRO-					,					
17. INDICATION(S) FOR USE					DUCTION?								
18. THERAPY DATES (from/to) 19. TI			ERAPY	DURA	TION	1							
	III. CONCOMITANT D	RUG(S)	AND	HIST	ORY	/							
22. CONCOMITANT DRUG(S	AND DATES OF ADMINISTR	RATION (exclude	those	used	to t	reat	reacti	on)				
23. OTHER RELEVANT HIST	ORY (e.g. diagnostics, allergic	s, pregna	ncy with	n last	mont	th of	perio	od, et	c.)				
	IV. MANUFACTUR	RER INF	ORMA	TION									
24a. NAME AND ADDRESS	OF MANUFACTURER												
	24b. MFR CONTROL NO.												
24c. DATE RECEIVED BY MANUFACTURER	24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL												
DATE OF THIS REPORT	25a. REPORT TYPE □ INITIAL □ FOLLOWUP												

CIOMS form	ICH-E2B field (R2)	ICH-E2B field (R3)
I. REACTION INFORMATION		
1. Patient initials (first, last)	B.1.1 Patient (name or initials)	D.1 Patient (name or initials)
1.a Country	A.1.2 Identification of the country where the reaction/event occurred	E.i.9 Identification of the Country Where the Reaction / Event Occurred
2. Date of birth (day/month/year)	B.1.2.1 Date of birth	D.2.1 Date of Birth
2.a Age (years)	B.1.2.2 Age at time of onset of reaction/event	D.2.2 Age at Time of Onset of Reaction / Event
2. Sex	B.1.5 Sex	D.5 Sex
4-6. Reaction onset (day/month/year)	B.2.i.4 Date of start of reaction/event	E.i.4 Date of Start of Reaction / Event
7.	B.2.i.0 Reaction/event as reported by the primary source	E.i.1 Reaction / Event as Reported by the Primary Source
Describe reaction(s)	B.2.i.8 Outcome of reaction/event at the time of last observation	E.i.7 Outcome of Reaction / Event at the Time of Last Observation
	B.4.k.16 Action(s) taken with drug	G.k.8 Action(s) Taken with Drug

CIOMS form	ICH-E2B field (R2)	ICH-E2B field (R3)			
	B.5.1	H.1			
	Case narrative including clinical course,	Case Narrative Including Clinical Course,			
	therapeutic measures, outcome and	Therapeutic Measures, Outcome and			
	additional relevant information	Additional Relevant Information			
13.	B.3.2	F.r.3.4			
(including relevant test lab data)	Results of tests and procedures relevant to	Result Unstructured Data (free text)			
(including relevant test lab data)	the investigation	Result Offstructured Data (free text)			
8-12.	A.1.5.1				
Check all appropriate to adverse reaction	Serious - at case level				
Patient died					
Involved or prolonged inpatient					
hospitalization	A.1.5.2	E.i.3.2			
Involved persistence or significant disability	Seriousness criteria - at case level	Seriousness Criteria at Event Level			
or incapacity					
Life threatening					
II.	B.4.k.1	G.k.1			
SUSPECT DRUG(S) INFORMATION	Characterization of drug role	Characterisation of Drug Role			
	B.4.k.2	G.k.2			
14.	Drug identification	Drug Identification			
Suspect drug(s)					
(include generic name)	B.4.k.3	G.k.4.r.7			
	Batch/lot number	Batch / Lot Number			
15.	B.4.k.6	G.k.4.r.8			
Daily dose(s)	Dosage text	Dosage Text			
16.	B.4.k.8	G.k.4.r.10			
Route(s) of administration	Route of administration	Route of Administration			
17.	B.4.k.11	G.k.7			
Indication(s) for use	Indication for use in the case	Indication for Use in Case			
18.	B.4.k.12	G.k.4.r.4			
Therapy dates	Date of start of drug	Date and Time of Start of Drug			

CIOMS form	ICH-E2B field (R2)	ICH-E2B field (R3)				
(from/to)	B.4.k.14 Date of last administration	G.k.4.r.5 Date and Time of Last Administration				
19. Therapy duration	B.4.k.15 Duration of drug administration	G.k.4.r.6 Duration of Drug Administration				
20. Did reaction abate after stopping drug? Yes/No/Na	B.4.k.16 Action(s) taken with drug	G.k.8 Action(s) Taken with Drug				
21. Did reaction reappear after reintroduction? Yes/No/Na	B.4.k.17.1 Did reaction recur on readministration?	G.k.9.i.4 Did Reaction Recur on Re-administration?				
III. CONCOMITANT DRUG(S) AND HISTORY	B.4.k.1 Characterization of drug role	G.k.1 Characterisation of Drug Role				
22. Concomitant drug(s) and dates of administration (exclude those used to treat reaction)	B.4.k.2 Drug identification B.4.k.12 Date of start of drug B.4.k.14 Date of last administration	G.k.2 Drug Identification G.k.4.r.4 Date and Time of Start of Drug G.k.4.r.5 Date and Time of Last Administration				
23. Other relevant history (e.g. diagnostics, allergics, pregnancy with last month of period, etc.)	B.1.7 Relevant medical history and concurrent conditions (not including reaction/event)	D.7.2 Text for Relevant Medical History and Concurrent Conditions (not including reaction / event)				
IV. MANUFACTURER INFORMATION						
24.a Name and address of manufacturer	A.1.11.1 Source(s) of the case identifier (e.g. name of the company, name of regulatory agency)	C.1.9.1.r.1 Source(s) of the Case Identifier				

CIOMS form	ICH-E2B field (R2)	ICH-E2B field (R3)			
24.b MFR control no.	A.1.11 Other case identifiers in previous transmissions	C.1.9 Other Case Identifiers			
24.c Date received by manufacturer	A.1.7b Date of receipt of the most recent information for this report	C.1.5 Date of Most Recent Information for This Report			
24.d Report source Study Literature Health professional	A.1.4 Type of report A.2.2 Literature reference(s) A.2.1.4 Qualification	C.1.3 Type of Report C.4.r.1 Literature Reference(s) C.2.r.4 Qualification			
25.a Report type Initial Follow-up	Transferring of correct dates (from 24.c) is based on the CIOMS Report type, i.e. if the report is initial or a follow-up.				
Date of this report	-	-			